Rocket Lab’s Revenue Rose 62%. Cash Burn Rose Too.

Rocket Lab’s top line stepped up again. Q2 FY2026 revenue reached $234.1 million, 62.0% above the $144.5 million reported a year earlier and $34.1 million above Q1 FY2026. Product revenue nearly doubled to $181.3 million from $92.7 million, while service revenue edged up to $52.7 million from $51.8 million. That mix matters because most of the incremental revenue came from products rather than launch and other services. Management also guided Q3 revenue to $250 million-$265 million, a midpoint of $257.5 million and sequential growth of 10.0% from Q2. If delivered, Q3 would set another quarterly revenue record, according to the Rocket Lab Q2 FY2026 earnings release.

Profitability improved, although Rocket Lab remains far from GAAP breakeven. Gross profit increased to $84.6 million from $46.4 million, lifting GAAP gross margin to 36.1% from 32.1%. The operating loss narrowed modestly to $57.5 million from $59.6 million even as revenue rose sharply, producing an operating margin of -24.6% versus -41.3% a year earlier. Adjusted EBITDA improved to a loss of $8.8 million from a loss of $27.6 million. Q3 guidance nevertheless calls for GAAP gross margin of only 29.0%-31.0%, below Q2, and an adjusted EBITDA loss of $17 million-$23 million. The next quarter is therefore expected to bring more revenue but weaker reported gross profitability and a larger adjusted loss.

Operating expenses continued to rise. Research and development expense increased 24.6% to $82.4 million, consistent with continued work on Neutron and other programs. Selling, general and administrative expense rose 49.6% to $59.7 million, including transaction costs and the growing organizational burden associated with acquisitions. Interest income of $16.5 million helped reduce the net loss to $49.3 million, or $0.08 per share, from $66.4 million, or $0.13 per share, a year earlier.

Cash generation was the clear weak point. Quarterly free cash flow was approximately -$0.11 billion, compared with -$0.06 billion in Q2 FY2025. For the first six months, operating cash outflow increased to $134.4 million from $77.5 million, while capital expenditure was $53.1 million. Accounts receivable, contract assets and inventory collectively absorbed substantial cash as the business scaled. Contract liabilities provided a partial offset, reflecting customer funding or billings ahead of revenue recognition. The detailed movements appear in the Rocket Lab Q2 FY2026 Form 10-Q.

The balance sheet changed more dramatically than the income statement. Cash and cash equivalents rose to $2.13 billion from $828.7 million at year-end, primarily because Rocket Lab raised approximately $1.53 billion through at-the-market equity offerings during the first half. Weighted-average common shares increased to 629.7 million in Q2 from 515.1 million a year earlier. The capital raise reduced liquidity risk and left debt modest relative to cash, but it also demonstrates that the stronger balance sheet came at a meaningful cost to existing owners through dilution.

The quarter supplied evidence for the strongest part of the Rocket Lab thesis: demand is not confined to a single launch product. Backlog reached a record $2.36 billion, up 137.0% year over year. Management also reported more than $437 million of new launch contracts across Electron, HASTE and Neutron during Q2 and after quarter-end, taking launch backlog above 90 missions. Separately, a $397 million award for Flatellite spacecraft and Neutron launches for the U.S. Space Force illustrates the potential value of combining spacecraft and launch capabilities. Contract totals include options, however, so backlog should not be treated as guaranteed revenue.

The margin progression is also encouraging. Rocket Lab’s quarterly operating margin improved from -49.5% in Q3 FY2024 to -28.4% in Q4 FY2025, -27.9% in Q1 FY2026 and -24.6% this quarter. That sequence suggests the revenue base is beginning to absorb fixed costs. The limitation is that Q3 guidance points to a temporary reversal in gross margin and adjusted EBITDA. One quarter of better operating leverage is not enough to establish a durable earnings model, especially while spending on Neutron and acquisitions remains elevated.

Neutron remains the central operational swing factor. Rocket Lab said production of the first Stage 1 tank was aligned with a target delivery of Neutron to the launch pad in Q4 FY2026. That is progress, but pad delivery is not the same as a successful inaugural launch or routine commercial operation. At the current valuation, Neutron must become more than a development program: it must expand Rocket Lab’s addressable market, launch reliably and contribute attractive economics without consuming disproportionate capital.

The announced Iridium transaction changes the strategic ambition but not yet the reported earnings base. Management’s stated goal is to become a company that designs, builds, launches and operates constellations. That could create a broader and more recurring revenue profile. It could also introduce acquisition financing, integration and operating risks before Rocket Lab has demonstrated positive free cash flow in its current configuration. Transaction terms and pro forma financial details needed for a full valuation adjustment are not disclosed in the supplied materials.

With no prior SageNoodle coverage, this report establishes rather than updates fair value. Conventional earnings and discounted free-cash-flow methods are not dependable because Rocket Lab has negative earnings, negative operating income and negative free cash flow. We therefore use an explicit enterprise-value-to-revenue framework based on annualized Q2 revenue, adjusted for scenario growth, and add approximately $2.12 billion of cash net of reported debt. We divide by 629.7 million weighted-average shares. This approach gives credit for the balance sheet but also captures the elevated share count after the equity issuance.

The bear case assumes $1.00 billion of forward revenue and a 10 times enterprise-value-to-revenue multiple. Adding net cash produces equity value of approximately $12.12 billion, or $19.20 per share. This case reflects slowing conversion of backlog, further Neutron delays, persistent negative cash flow and limited value creation from acquisitions.

The base case assumes $1.10 billion of forward revenue and a 17 times multiple. That yields enterprise value of $18.70 billion and equity value of approximately $20.82 billion after net cash, or $33.10 per share. The assumptions require continued strong growth, improving operating leverage and meaningful strategic value from Rocket Lab’s integrated model, while stopping short of assuming flawless Neutron commercialization.

The bull case assumes $1.30 billion of forward revenue and a 30 times multiple, producing equity value of approximately $41.12 billion, or $65.30 per share. This outcome requires successful Neutron execution, strong conversion of government awards and backlog, continued rapid space-systems growth and confidence that Rocket Lab can ultimately generate attractive margins. Even this demanding case offers limited upside from the current $61.96 price.

Base fair value is therefore $33.10 per share. The ratio of fair value to price is approximately 0.53, meeting SageNoodle’s definition of Overvalued. The quarter was operationally positive, but a $39.0 billion market capitalization already discounts progress well beyond the reported $234.1 million quarterly revenue base. P/E and EV/EBITDA are not meaningful because earnings and EBITDA remain negative; the supplied TTM free-cash-flow yield is -0.9%.

The valuation could prove too conservative if Rocket Lab converts backlog faster than assumed and Neutron enters service with limited delay or incremental capital. The company’s integrated offering may also deserve a higher multiple if customers increasingly award combined spacecraft-and-launch contracts, as the Space Force award suggests. An Iridium combination could add recurring communications revenue and strategic scarcity value, but the supplied documents do not provide enough transaction detail to quantify that possibility.

The operating thesis could instead fail if Neutron misses technical or schedule milestones, if Q3’s guided gross-margin decline persists, or if working-capital investment continues to outpace revenue growth. First-half inventory increased materially, and operating cash use worsened despite higher revenue and better accounting margins. Persistent cash consumption would make dilution an ongoing concern even with the current cash balance.

Government and defense awards also create concentration and execution risks. Contract options may not be exercised, program timing can move, and technically demanding fixed-price or milestone-based work can pressure margins. Finally, integrating Mynaric, Motiv and potentially Iridium while developing Neutron increases managerial complexity. The quarter improved evidence of demand and scale, but it did not reduce the number of major programs Rocket Lab must execute simultaneously.